240. Phenylketonuria Clinical trials / Disease details
Clinical trials : 138 / Drugs : 106 - (DrugBank : 11) / Drug target gene : 1 - Drug target pathways : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04256655 (ClinicalTrials.gov) | December 1, 2020 | 28/1/2020 | Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients | A Phase 1, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 After Multiple Ascending Oral Dose Administration to Patients With Phenylketonuria (PKU). | Phenylketonurias | Drug: cohort 1 0.225g;Drug: Cohort 2 0.75g;Drug: Cohort 3 2.25 g | Nestlé | NULL | Withdrawn | 18 Years | 65 Years | All | 0 | Phase 1 | NULL |